Sanofi, Multiple Sclerosis and Denali
Sanofi, Denali Abandon Mid-Stage Multiple Sclerosis Study on Disappointing Data
Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic lateral sclerosis, forcing the company to discontinue its development a few months later.
Sanofi flunks midphase multiple sclerosis study, dealing another blow to Denali pact
Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after failing to meet its primary and secondary endpoints,
Denali-Sanofi scraps mid-stage study for multiple sclerosis drug
Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary study goals.
Sanofi, Denali face another mid-stage setback for neurology therapy
Sanofi (NASDAQ:SNY) has failed in another mid-stage trial for DNL788, an experimental therapy developed with Denali Therapeutics (NASDAQ:DNLI) for neurological conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis.
A setback for the Denali-Sanofi partnership
Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup Denali Therapeutics to go after a promising new target called RIPK1. That partnership has not gone well.
Toxic protein may contribute to amyotrophic lateral sclerosis development
A toxic version of a certain protein may affect brain, spinal cord and skeletal muscle tissues differently, leading to the ...
stockhead14h
Dr Boreham’s Crucible: Can this small Aussie company meet MND’s sizeable need?
True to its history of reinvention and repurposing, Pharmaust will be renamed Neurizon Therapeutics after shareholders ...
The Charlotte Post3d
A fatal disease sparks the spirit of advocacy, philanthropy
Hall, founder of Beacon of Hope for ALS, aims to lift people up and help them after their diagnosis. Amyotrophic lateral ...
Medical Xpress6d
Amyotrophic Lateral Sclerosis
Researchers at the Francis Crick Institute and the UCL Queen Square Institute of Neurology have developed DNA molecules which contain "invisibility cloak" sequences, preventing healthy cells from ...
Cosumnes Oaks dedicates season to ailing head coach: ‘A positive man, husband, father’
Billings is a world history and social science teacher on the Elk Grove Unified School District campus and has coached the varsity program for three seasons. He announced early this season that he was ...
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
PRESS RELEASEAB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIODClinical ...
Frontiers22h
Biophysical Insights into the Molecular Mechanisms of Neurodegeneration
Neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, Huntington’s, and amyotrophic lateral sclerosis (ALS), are characterized by the progressive loss of structure and function of neurons, ...